Earnings summaries and quarterly performance for aTYR PHARMA.
Executive leadership at aTYR PHARMA.
Board of directors at aTYR PHARMA.
Research analysts covering aTYR PHARMA.
Recent press releases and 8-K filings for ATYR.
aTyr Pharma Faces Securities Class Action Lawsuit Over Failed Drug Trial
ATYR
Legal Proceedings
- aTyr Pharma (NASDAQ: ATYR) is facing a securities class action lawsuit filed by Hagens Berman, with a December 8, 2025, deadline for investors to move the Court for appointment as lead plaintiff.
- The lawsuit alleges that aTyr and its executives provided materially false and misleading information about the efficacy of its drug, Efzofitimod, leading to an 83% single-day stock collapse on September 15, 2025, after the Phase 3 EFZO-FIT study failed to meet its primary endpoint.
- The litigation focuses on the alleged concealment of adverse facts concerning Efzofitimod's capability to allow patients to completely taper their steroid usage.
- The Class Period for investors who purchased ATYR shares and suffered substantial losses is from November 7, 2024, through September 12, 2025.
1 day ago
aTyr Pharma Faces Securities Class Action Lawsuit Following Drug Trial Failure
ATYR
Legal Proceedings
- Hagens Berman reminds investors of the December 8, 2025, deadline to move for lead plaintiff in a securities class action lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR).
- The lawsuit alleges that aTyr provided materially false and misleading information about the efficacy of its drug, Efzofitimod, leading investors to purchase stock at artificially inflated prices.
- This litigation follows a catastrophic 83% single-day stock collapse on September 15, 2025, after the company's flagship drug trial, the Phase 3 EFZO-FIT study, failed to meet its primary endpoint.
- The Class Period for the lawsuit is defined as November 7, 2024, through September 12, 2025.
3 days ago
ATYR Prepares for Q1 2026 FDA Meeting on Efzofitimod for Sarcoidosis
ATYR
New Projects/Investments
Guidance Update
- ATYR is preparing for an FDA meeting in Q1 2026 to discuss the efzofitimod data package for sarcoidosis, including pre-specified endpoints like steroid reduction, steroid withdrawal, and PROs, as well as post-hoc analyses.
- The EFZO-FIT study showed a high placebo response in steroid reduction (60% reduction, 40% off steroids), but efzofitimod demonstrated over 70% steroid reduction and over 50% of patients off steroids. Clinical benefit, particularly in quality of life improvements (PROs), was observed only in the treatment population.
- Potential outcomes from the FDA meeting include a green light for a Biologics License Application (BLA) or the requirement for an additional confirmatory study, for which ATYR is preparing a trial design, possibly using KSQ Lung as a primary endpoint.
- Enrollment for the EFZO-CONNECT study (SSc-ILD) is anticipated to conclude in the first half of 2026, with full data expected in the second half of 2026. Interim data showed improvement in skin subscores.
5 days ago
aTyr Pharma discusses EFZO-FIT data and Q1 2026 FDA meeting
ATYR
Clinical Trial Results
Regulatory Approval
Guidance Update
- aTyr Pharma presented full topline results from the EFZO-FIT data at ERS, detailing steroid reduction, withdrawal, and positive outcomes from three Patient-Reported Outcome (PRO) instruments (KSQ Lung, KSQ General Health, and Fatigue Assessment Score).
- Despite an unexpectedly high placebo response in steroid reduction in the EFZO-FIT study, the company highlights that PRO differences indicating improved quality of life and reduced fatigue were observed only in the treatment population, suggesting clinical benefit.
- The company is preparing for an FDA meeting in Q1 2026 to discuss the comprehensive EFZO-FIT data package for Efzofitimod in sarcoidosis.
- Potential outcomes from the FDA meeting include a green light for a Biologics License Application (BLA) filing or a requirement for an additional confirmatory study, with aTyr preparing a protocol that could feature KSQ Lung as a primary endpoint.
- Enrollment for the EFZO-CONNECT study (SSC ILD) is projected to conclude in the first half of 2026, with data expected in the second half of 2026.
5 days ago
aTyr Pharma Discusses EFZO-FIT Data and Upcoming FDA Meeting
ATYR
New Projects/Investments
Guidance Update
- aTyr Pharma discussed the EFZO-FIT data from the ERS presentation, noting a high placebo response in steroid reduction but emphasizing clear clinical benefit in patient-reported outcome (PRO) instruments, including KSQ Lung, KSQ General Health, and the Fatigue Assessment Scale.
- The company is preparing for an FDA meeting in Q1 2026 to review the totality of the EFZO-FIT data package, which includes both pre-specified endpoints (e.g., steroid reduction, PROs, safety, FVC) and post-hoc analyses (e.g., subpopulations, biomarkers).
- CEO Sanjay Shukla stated the company is ready for potential FDA outcomes, including a Biologics License Application (BLA) filing or the need for an additional confirmatory study, for which a new trial protocol is being prepared.
- The King's Sarcoidosis Questionnaire (KSQ) Lung is being considered as a potential primary endpoint for future studies, having been validated with the FDA's PRO division.
- Enrollment for the EFZO-CONNECT™ study (SSc-ILD) is projected to finish in the first half of 2026, with data expected in the second half of 2026; interim data showed improvement in skin subscores.
5 days ago
aTyr Pharma Faces Securities Class Action Lawsuit
ATYR
Legal Proceedings
- Global plaintiffs' rights law firm Hagens Berman has filed a securities class action lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR).
- The lawsuit alleges that aTyr provided materially false and misleading information regarding the efficacy of its drug, Efzofitimod, after its Phase 3 EFZO-FIT study failed to meet its primary endpoint.
- This failure led to an 83% single-day stock collapse on September 15, 2025, with the stock falling from $6.03 to $1.02.
- Investors who purchased ATYR shares during the Class Period (November 7, 2024, through September 12, 2025) have until December 8, 2025, to move the Court for appointment as lead plaintiff.
5 days ago
aTyr Pharma Faces Securities Class Action Investigation
ATYR
Legal Proceedings
- Faruqi & Faruqi, LLP is investigating aTyr Pharma for potential federal securities law violations, alleging false and/or misleading statements regarding the efficacy of its drug, Efzofitimod.
- The investigation covers securities purchased between January 16, 2025, and September 12, 2025.
- The complaint highlights that in the EFZO-FIT study, Efzofitimod failed to show a significant change in mean daily oral corticosteroid dose at week 48, with complete steroid withdrawal achieved by 52.6% of patients on efzofitimod versus 40.2% on placebo.
- Following the release of these results, aTyr Pharma's stock price dropped by 83.25%, from $6.03 on September 12th to $1.01 on September 15th.
- Investors have until December 8, 2025, to seek the role of lead plaintiff in the class action lawsuit.
8 days ago
aTyr Pharma Faces Securities Class Action Lawsuit After Drug Trial Failure
ATYR
Legal Proceedings
- Hagens Berman has filed a securities class action lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR), alleging the company provided materially false and misleading information about the efficacy of its drug, Efzofitimod.
- This litigation follows an 83% single-day stock collapse on September 15, 2025, after the Phase 3 EFZO-FIT study for Efzofitimod failed to meet its primary endpoint, specifically its steroid-tapering capability.
- Investors who purchased ATYR shares during the Class Period (November 7, 2024, through September 12, 2025) and suffered substantial losses are urged to act by the December 8, 2025, lead plaintiff deadline.
Nov 28, 2025, 10:40 PM
aTyr Pharma Faces Securities Class Action Lawsuit Over Failed Drug Trial
ATYR
Legal Proceedings
- Hagens Berman reminds investors of the December 8, 2025, deadline to move for lead plaintiff in a securities class action lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR).
- The lawsuit alleges that aTyr provided materially false and misleading information about its drug, Efzofitimod, which failed to meet its primary endpoint in the Phase 3 EFZO-FIT study.
- This failure resulted in an 83% single-day stock collapse for ATYR, with shares falling from $6.03 to $1.02 on September 15, 2025.
- The Class Period for investors who suffered substantial losses due to alleged undisclosed trial flaws is November 7, 2024, through September 12, 2025.
Nov 27, 2025, 6:31 PM
ATYR Pharma Faces Securities Class Action Amid Missed Q3 Estimates and Drug Efficacy Concerns
ATYR
Earnings
Legal Proceedings
Profit Warning
- ATYR Pharma reported third-quarter results on November 6, 2025, with a GAAP EPS loss of -$0.26 and revenues of $190,000, both missing Wall Street estimates.
- The company is facing securities class action litigation alleging materially false and misleading information about the efficacy of its drug, Efzofitimod.
- The EFZO-FIT study for Efzofitimod did not meet its primary endpoint, leading to the stock plummeting over 83% on September 15, 2025.
- The alleged Class Period for the litigation has been expanded to November 7, 2024 \u2013 September 12, 2025, with a Lead Plaintiff Deadline of December 8, 2025.
Nov 26, 2025, 1:50 PM
Quarterly earnings call transcripts for aTYR PHARMA.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more